Blueprint Medicines CORP Form 4 insider transactions
Kate Haviland, CEO of Blueprint Medicines, received 40,000 restricted stock units and stock options for 80,000 shares on March 1, 2024, according to a Form 4 filing.
Michael Landsittel, CFO of Blueprint Medicines, was granted stock options and restricted stock units on March 1, 2024, according to a recent SEC Form 4 filing.
Form 4: Blueprint Medicines Executive Percy H. Carter Receives Stock Options and Restricted Stock Units
Percy H. Carter, Chief Scientific Officer of Blueprint Medicines Corp, was granted 12,500 restricted stock units and stock options for 25,000 shares on March 1, 2024.
Ariel Hurley, Principal Accounting Officer of Blueprint Medicines Corp, reports the acquisition of stock options and restricted stock units.
Christopher Murray, Chief Technical Operations Officer at Blueprint Medicines, reports the acquisition of restricted stock units and a sale of common stock under a pre-arranged trading plan.
Christopher Murray, Chief Technical Operations Officer at Blueprint Medicines, exercised stock options and sold shares on February 28, 2024, according to a recent SEC filing.